Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational ...

Stoke Therapeutics shares fell Tuesday after the company announced the resignation of its CEO. Dr. Edward Kaye is stepping down from the position Wednesday, with the company beginning a search ...

Biogen and Stoke Therapeutics have reached an agreement to develop and commercialize zorevunersen, a potential first-in-class disease-modifying therapy for Dravet syndrome, in all regions outside of ...

Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet syndrome, with the deal worth $550m. Up to 38,000 people in the US, UK, EU and ...

Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a treatment for Dravet syndrome, a severe form of epilepsy that starts in childhood.

Biogen and Stoke Therapeutics have agreed to collaborate on Stoke's proposed zorevunersen treatment for the severe genetic epilepsy Dravet syndrome in a deal potentially worth hundreds of millions ...

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.

(RTTNews) - Biogen Inc. (BIIB) and Stoke Therapeutics, Inc. (STOK) Tuesday announced partnership to develop and sell zorevunersen, Stoke's drug candidate for the treatment of Dravet syndrome, in ...

Currently, it is estimated that up to 38,000 people are living with Dravet syndrome in the U.S., UK, EU-4 and Japan. 1 ...